

Summary of Studies Supporting USDA Product Licensure

Establishment Name	Boehringer Ingelheim Animal Health USA Inc.
USDA Vet Biologics Establishment Number	124
Product Code	1515.22
True Name	Equine Rhinopneumonitis-Influenza Vaccine, Killed Virus
Tradename(s) / Distributor or Subsidiary (if different from manufacturer)	Vetera 2xp - Boehringer Ingelheim (Canada) Ltd. Vetera 2xp - No distributor specified
Date of Compilation Summary	October 26, 2020

Disclaimer: Do not use the following studies to compare one product to another. Slight differences in study design and execution can render the comparisons meaningless.

Study Type	Efficacy											
Pertaining to	Equine herpe	svirus	type 1 (E	HV-1)								
Study Purpose	Demonstratio EHV-1	on of ef	ficacy ag	ainst respiratory disease ca	used by							
Product Administration	Two doses, a	dminis	tered intr	amuscularly, 21 days apart								
Study Animals	40 horses (20	40 horses (20 vaccinates, 20 controls), 4-5 months of age										
Challenge Description	Equine herpe	svirus	type 1 ad	ministered 15 days post-fin	al							
	vaccination											
Interval observed after	Horses were	observe	ed daily f	or 14 days post-challenge								
challenge												
Results	See raw data	on foll	owing pa	ges.								
	signs of resp classified as	iratory "norm ssificat	disease. al", "mil tion of th	r the presence of nasal dis The severity of nasal discl d", or "moderate" accordi e nasal scores.	narge was							
				a category were:								
		ormal	Mild	Moderate								
	Control 0 10 10											
	Vaccine 6 11 3											
USDA Approval Date	January 28, 2	009										

Nasal Discharge:

						Day	y Post	tchall								
Treatment	ID	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
	1					1.5			1.5	1.5	1	1.5				
	2						1.5		1.5	1.5	1	1.5	1.5	1		
	3						1.5			1.5	2			1.5		
	4			1		2	1.5		1.5	1.5	1.5	1.5				1.5
	5				2	2	2	1	4	2	2	1.5	1.5		1.5	
	6			1		4	6	4	4	4	4	2	2	2		
	7					1.5	1.5	1.5	1.5	1.5	2	4	1		1	1
	8								1.5	2	2	4	1.5	4	2	1.5
	9				1	1.5	1.5	1.5	1.5	1.5	2	1.5				
Controls	10			1			1		1.5	1.5	2	4	4		1.5	1.5
(20 horses)	11						1.5	1.5	1.5		2		1.5	1.5	1.5	
	12						1.5	1.5		2						1.5
	13						2	1.5	1.5	2	2	2	1.5	1.5	1.5	4
	14				1.5	2		1.5		1.5	1.5	1.5			2	2
	15				1	2	1.5	1	1.5		4		1		4	1.5
	16					1.5	1.5	2	2	2	2	1.5	1	1	4	2
	17					1.5		1			1.5	2		1.5	1.5	
	18						1	1.5	1.5	4	4	2	1.5	4	1.5	2
	19				1	2	1.5		1.5	2	4	1	1.5		1	
	20						1.5	1.5	2	1.5	2				1.5	
	1					1		1				1.5				
	2				1											
	3						1	1.5	4		1.5	1.5			1	
	4				1						2	1				
	5				1				1	1						
	6				1	1.5						1.5	2	2	2	1.5
	7							2					1.5			
	8															
	9					2	1.5	2	2	6	2	1.5		1.5	4	2
Vaccinates	10								1				1	1.5		
(20 horses)	11				1		1.5		2	2	1	1.5				
	12				1		1.5	2	1.5	2	2	2		2	2	1.5
	13				1.5						1.5	1.5			1.5	1.5
	14							1	1			1			1.5	
	15				1											
	16				1		1.5	1.5	1			1.5				
	17															
	18						1			1.5		1.5				
	19														6	2
	20															

Day Postchallenge

Scoring:

Blank is 0 =none;

1 = slight serous, as may be observed in both normal and diseased horses;

- 1.5 = very slight mucopurulent discharge;
- 2 = moderate clear serous discharge, or slight mucopurulent discharge;
- 3 = abundant serous discharge;
- 4 = moderate mucopurulent discharge;
- 6 = heavy mucopurulent discharge

Study Type	Efficacy								
Pertaining to	Equine herpesvirus ty	pe 4 (EHV-4)							
Study Purpose	Demonstration of effi EHV-4		tory disease cau	ised by					
Product Administration	Two doses, administe	red intramuscularly,	21 days apart						
Study Animals	40 horses (20 vaccina								
Challenge Description	Equine herpresvirus type 4 administered 14 days post-final vaccination								
Interval observed after challenge	Horses were observed	l daily for 14 days p	ost-challenge						
Results	See raw data on follo	wing pages.							
	The horses were asses discharge as signs of a combined findings (n "mild" or "moderate"	respiratory disease. ' asal and ocular disch	The severity of narge) were class	the ssified as					
	Disease status	Nasal score	Ocular score						
	Normal = 0	0 or 1	0 or 1						
	Mild = 1	0 or 1	2						
	Mild = 1	1.5, 2, or 3	any						
	Moderate = 2	4 or 6	any						
	Moderate respiratory disease was observed in 8/20 placebo controls and 1/20 vaccinated horse, and mild disease was observed in 12/20 placebo controls and 17/20 vaccinated horses. None of the placebo controls remained healthy following challenge, whereas 2 vaccinates showed no signs of respiratory disease.								
USDA Approval Date	May 31, 2011								

Ocular Discharge:

			1 -	1			'ostcl			1 -	1	1			1	
Treatment	Animal	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
Ŧ	1								2		2	2	2		2	2
I	2				2	2	2	2	2	2	2	2	2	2	2	
	3				2	2		2	2	2		2	2	2	2	2
	4				2	2	2	2	2		2	2	2		2	
	5					2					2			2	2	2
	6				2		2	2	2	2	2	2	2	2	2	
	7					2	2	2	2	2	2	2		2		2
	8				2		2	2		2						
	9				2	2	2	2	2	2	2	2	2	2	2	2
Controls	10				2	2	2	2	2	2		2	2	2	2	
	11				2	2	2	2	2	2	2	2	2	2	2	2
	12												2		2	
	13															
	14				2	2	2	2	2		2	2	2	2		2
	15					2	2	2		2	2	2	2			
	16							2		2	2	2	2			
	17					2		2		2	2	2	2	2	2	2
	18				2	2	2	2	2	2	2	2	2	2		
	19				2	2	2	2			2				2	2
	20				2	2	2	2	2	2	2	2			1	
	1											2	2	2		
	2					2									1	
	3						2		2	2				2	2	2
	4		+		2	<u> </u>		2			2			-	-	
	5		+		-	<u> </u>		-	2	<u> </u>						2
	6		+		<u> </u>	<u> </u>	<u> </u>	+	-	2	2					
	7					<u> </u>	2	2			-					
	8					2	2	2	2		2					
	9						-	-	-		-					2
	10							2					2		2	2
Vaccinates	11							-								
	12		+			<u> </u>				+	2	2	2		+	2
	13		+			2	2		2	+	1-			2	2	2
	14		+	+		- ۲	1-			+	+				1-	
	15			-	<u> </u>		2	2		-						
	16						-	-		-	-				-	
	17				2			2	2	2		2		2	2	2
	18		+		-			2	-	2		2		2	2	2
	18									-		2		2	-	
	20															
	20		1													

Day Postchallenge

Scoring:

Blank is 0=none 1=mild or moderate 2=severe

Nasal Discharge:

Day Postchallenge

]	Day I	Postcl	naller	ige								
Treatment	Animal	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14
	1				1	1			1	2	3		3		3	
	2				2	3	3	2	2	3	3	2	4	3	3	2
	3				3	3		2	4			3	3	2	2	
	4					4	4	3	3	4	3	3			2	2
	5					2	3	3	3		3	2	2		2	3
	6						3		2	4	3	3	2	3	2	
	7				1	2	1	2	2	2	2	3	2		2	2
	8								2		2					
	9							2	2	3	2	2	2	3		
Controls	10				3	4	3	3	3	2		2	2	2	2	2
	11															1
	12						3		2	2	2				3	3
	13					3	2	2	2	2	1	2	2			
	14				2	3	4	4	2	4	2	4	3	4	3	
	15				1		3	3	3	3		3	3			2
	16				3	3	3	4	2	4	4	3	4	2	2	2
	17					1		2	2	3	2		3	3		\square
	18				2		3	3	2	2	2	2	3	2	2	2
	19						1	4	2	3		3			2	3
	20				2			2	2		3		2	2	2	
	1								2					2	3	\square
	2															\square
	3									1	2				3	\square
	4				1											\square
	5								2				3			2
	6										3					
	7					1										
	8							2	3	1	3					
	9											1				2
Variation	10										3		2			
Vaccinates	11								2							
	12								3	2	3	1	3			2
	13							1	3				2	2	2	
	14									2				2		
	15								2							
	16											1				
	17				2					3				3	2	<u> </u>
	18									4	2		2		2	<u> </u>
	19															<u> </u>
	20								2			3	3			<u> </u>

Scoring:

Blank is 0 = none

1 = slight clear serous, as may be observed in both normal and diseased horses;

1.5 = very slight mucopurulent discharge, one or both nostrils;

2 = moderate clear serous discharge, easily seen in one or both nostrils;

3 = abundant clear serous discharge typically seen only in diseased horses;

4 = moderately mucopurulent, in large quantities in both nostrils;

5 = heavy mucopurulent discharge in large amounts in both nostrils


Study Type	Efficacy
Pertaining to	Equine influenza virus
Study Purpose	Demonstration of 6-month duration of immunity against
,	respiratory disease caused by equine influenza
Product Administration	Two doses, administered intramuscularly, 21 days apart.
	Vaccinates received test product, and controls received
	adjuvanted diluent.
Study Animals	30 horses (20 vaccinates, 10 controls), 5-6 months of age
Challenge Description	Influenza A/eq/Ohio/2003 administered 184 days post-final
	vaccination
Interval observed after	Horses were observed daily for 10 days post-challenge
challenge	
Results	See tables at the end of document for data.
	 Clinical Signs: An animal was considered positive (affected by challenge) if the animal exhibited: Fever (temperature >102.5°F), OR Nasal discharge (moderate serous discharge or mucopurulent discharge), OR Ocular discharge A total of 9/10 (90%) controls were positive as compared to only 9/20 (45%) vaccinates. There were no adverse reactions to vaccine administration at any timepoint.
USDA Approval Date	September 7, 2010

		Days Post-challenge										
Treatment	Clinical Sign	0	1	2	3	4	5	6	7	8	9	10
Controls												
	Fever											
1	Nasal discharge						+	+	+	+		
	Ocular discharge						+			+		+
	Fever											
2	Nasal discharge			+			+		+	+	+	
	Ocular discharge						+	+			+	+
	Fever											
3	Nasal discharge							+		+		
	Ocular discharge			+			+			+		+
	Fever											
4	Nasal discharge											
	Ocular discharge						+	+	+			+
	Fever											
5	Nasal discharge					+	+	+	+	+	+	
	Ocular discharge											
	Fever											
6	Nasal discharge					+			+		+	+
	Ocular discharge											+
	Fever											
7	Nasal discharge			+			+		+			+
	Ocular discharge			+				+				
	Fever								+			
8	Nasal discharge						+	+	+			+
	Ocular discharge			+	+		+	+				+
	Fever											
9	Nasal discharge											
	Ocular discharge											
	Fever											
10	Nasal discharge						+	+	+	+	+	
	Ocular discharge					+	+		+	+	+	

					D	ays P	ost-ch	allen	ge			
Treatment	Clinical Sign	0	1	2	3	4	5	6	7	8	9	10
Vaccinates												
	Fever											
1	Nasal discharge											
	Ocular discharge											
	Fever											
2	Nasal discharge											
	Ocular discharge											
	Fever											
3	Nasal discharge											
	Ocular discharge						+			+	+	
	Fever											
4	Nasal discharge								+			
	Ocular discharge											
	Fever											
5	Nasal discharge											
	Ocular discharge											
	Fever											
6	Nasal discharge											
	Ocular discharge											
	Fever											
7	Nasal discharge											
	Ocular discharge											
	Fever											
8	Nasal discharge											
	Ocular discharge											
	Fever											
9	Nasal discharge											
	Ocular discharge											
	Fever						+					
10	Nasal discharge							+	+			
	Ocular discharge									+		+
	Fever											
11	Nasal discharge						+			+	+	+
	Ocular discharge											
	Fever											
12	Nasal discharge									+		
	Ocular discharge						1		1	1		


					D	ays P	ost-ch	allen	ge			
Treatment	Clinical Sign	0	1	2	3	4	5	6	7	8	9	10
Vaccinates												
	Fever											
13	Nasal discharge					+						+
	Ocular discharge											
	Fever											
14	Nasal discharge											
	Ocular discharge											
	Fever											
15	Nasal discharge											
	Ocular discharge						+		+			
	Fever											
16	Nasal discharge							+				
	Ocular discharge											
	Fever											
17	Nasal discharge											
	Ocular discharge											
	Fever											
18	Nasal discharge											
	Ocular discharge											
	Fever											
19	Nasal discharge							+		+		
	Ocular discharge											
	Fever											
20	Nasal discharge											
	Ocular discharge											

Study Type	Efficacy
Pertaining to	Equine influenza virus
Study Purpose	Demonstration of efficacy against respiratory disease and shedding caused
	by equine influenza
Product	Two doses, administered intramuscularly, 21 days apart.
Administration	
Study Animals	37 horses (18 vaccinates, 19 controls), approximately 9-10 months of age
Challenge	Influenza A/eq/Ohio/2003 administered 3 weeks post-final vaccination
Description	
Interval	Horses were observed, and nasal swabs were collected, daily for 15 days
observed after	post-challenge.
challenge	
Results	See tables at the end of document for data.
	Clinical Signs:
	An animal was considered positive (affected by challenge) if the animal
	exhibited the following at any post-challenge observation point:
	• Fever (temperature $\geq 102.5^{\circ}$ F), OR
	• Ocular discharge, OR
	• Nasal discharge (very slight mucopurulent discharge, or worse)
	Duration of disease was calculated from the date the animal was first observed to be positive to the date of last positive observation for that animal. Based on this calculation, the median duration of disease for the controls was determined to be 11 days as compared to 3 days for the vaccinates.
	Nasal shedding of influenza virus was evaluated through nasal swab virus isolation results. An animal was considered positive if virus was isolated from nasal swabs on one or more occasions following challenge.
	0/18 vaccinates shed virus and 12/19 controls shed virus.
	There were no adverse reactions to vaccine administration at any timepoint.
USDA	April 8, 2013
Approval Date	
**	



Ocular Discharge: 0=none; 1=mild to moderate; 2=severe

Nasal Discharge: 0=none; 1=slight clear serous, as may be observed in both normal and diseased horses; 1.5=very slight mucopurulent discharge, one or both nostrils; 2=moderate clear serous discharge, easily seen in one or both nostrils; 3=Abundant clear serous discharge typically seen only in diseased horses; 4=moderately mucopurulent, in large quantities in both nostrils; 5=heavy mucopurulent discharge in large amounts in both nostrils



Ocular Discharge: 0=none; 1=mild to moderate; 2=severe

Nasal Discharge: 0=none; 1=slight clear serous, as may be observed in both normal and diseased horses; 1.5=very slight mucopurulent discharge, one or both nostrils; 2=moderate clear serous discharge, easily seen in one or both nostrils; 3=Abundant clear serous discharge typically seen only in diseased horses; 4=moderately mucopurulent, in large quantities in both nostrils; 5=heavy mucopurulent discharge in large amounts in both nostrils

Study Type	Efficacy
Pertaining to	Equine influenza
Study Purpose	Demonstration of efficacy against respiratory disease caused by
	equine influenza A2 strain Richmond 07
Product Administration	Two doses, administered intramuscularly, 21 days apart
Study Animals	20 horses (20 vaccinates), 12 months of age
Challenge Description	Not applicable
Interval observed after	Not applicable
challenge	
Results	This product class allows the manufacturer to update micro- organisms in this vaccine under expedited procedures to respond to emerging needs. Abbreviated data to support influenza strain updates to the product composition were evaluated by USDA- APHIS and found to be acceptable based on regulations and policies at the time of approval. Full vaccination-challenge studies may not have been required for these updates.
USDA Approval Date	February 2, 2012

Study Type	Efficacy						
Pertaining to	Equine influenza						
Study Purpose	Demonstration of efficacy against respiratory disease caused by						
	equine influenza A2 strain Kentucky 95						
Product Administration	Two doses, administered intramuscularly, 21 days apart						
Study Animals	20 horses (20 vaccinates), 12 months of age						
Challenge Description	Not applicable						
Interval observed after	Not applicable						
challenge							
Results	This product class allows the manufacturer to update micro- organisms in this vaccine under expedited procedures to respond to emerging needs. Abbreviated data to support influenza strain updates to the product composition were evaluated by USDA- APHIS and found to be acceptable based on regulations and policies at the time of approval. Full vaccination-challenge studies may not have been required for these updates.						
USDA Approval Date	February 2, 2012						

Study Type	Safety						
Pertaining to	All fractions						
Study Purpose	To demonstrate safety under field conditions at three different test sites						
Product	2 doses given	n intramusc	ularly 21 days a	apart			
Administration							
Study Animals			th two doses inc	luding:			
			nonth-old foals				
			month-old foals				
Challange		1 year or ol	der norses				
Challenge Description	Not Applicat	ble					
Interval	Horses were	observed or	n Days 0, 1 and	3 followi	ng the firs	t vaccinat	ion and
observed after			wing the second		-		
vaccination	injection site						
Results			reactions obser	ved at any	of the th	ree sites.	Local
			re summarized				
	N 1 S 1	a.					
	North Dakot	a Site:		Tuon	sient		
	Summary	Total	Number		on Site	Number	Normal
	j samma y	Number	with 2 doses	•	lling		
	Age			1 st dose	2 nd dose	1 st dose	2 nd dose
	2-4 mo	149	149	0	0	149	149
	5-7 mo	0	0	n/a	n/a	n/a	n/a
	8-11 mo	0	0	n/a	n/a	n/a	n/a
	1 yr-5yr	23	23	0	0	23	23
	6-15 yr	121	121	0	0	121	121
	>16 yr	3	3	0	0	3	3
	Total	296	296	0	0	296	296
	California Si	te:					
	SummaryTotal NumberNumber with 2 dosesTransient Injection Site 						
	Age			1 st dose	2 nd dose	1 st dose	2 nd dose
	2-4 mo	0	0	n/a	n/a	n/a	n/a
	5-7 mo	5	5	0	0	5	5
	8-11 mo	0	0	n/a	n/a	n/a	n/a
	1 yr-5yr	25	25	0	4	25	21
	6-15 yr	15	15	0	3	15	12
	>16 yr	6	6	0	1	6	5
	Total	51	51	0	8*	51	43
			were minimal.	The reported	d reactions	were mild,	transient,
	non-painful in	njection swell	lings.				

	Missouri Site	•						
	Summary	Total Number	Number with 2 doses	Transient Injection Site Swelling		Number Normal		
	Age			1 st dose	2 nd dose	1 st dose	2 nd dose	
	2-4 mo	55	54	0	0	55	54	
	5-7 mo	15	14	0	0	15	14	
	8-11 mo	0	0	n/a	n/a	n/a	n/a	
	1 yr-5yr	134	132	0	0	134	132	
	6-15 yr	68	68	0	0	68	68	
	>16 yr	7	7	0	0	7	7	
	Total	279	275	0	0	279	275	
	Total Across Three Sites: Total Transient Site Total Number with 2 doses Swelling				Number Normal			
		Number	with 2 doses	1 st dose	2^{nd} dose	1 st dose	2 nd dose	
	North Dakota	296	296	0	0	296	296	
	California	51	51	0	8*	51	43	
	Missouri	279	275	0	0	279	275	
	Total	626	622	0	8*	626	614	
	*Postvaccination reactions were minimal and described as mild, transient, non-painful swellings after the second vaccination in eight (8) older, heavily vaccinated horses. There were no systemic reactions observed.							
USDA	February 14,	2012						
Approval Date								

Study Type	Safety
Pertaining to	All fractions
Study Purpose	To demonstrate safety in pregnant mares under field conditions at
	two different test sites
Product	Two intramuscular doses, given 16-28 days apart. 54 pregnant mares
Administration	were injected with placebo and 325 pregnant mares were vaccinated
	with test product.
Study Animals	Three hundred seventy-nine pregnant mares at two locations were
	included in the study. The mares were confirmed to be pregnant by
	serum hormonal evaluation on the day of the first vaccination.
Challenge	Not applicable
Description	
Interval observed	1 st and 2 nd trimester: Mares observed immediately after vaccination
after vaccination	and daily for overall health and for abortion. Resulting foals were
	observed daily for 7 days following birth.
	3 rd trimester: Mares observed immediately after vaccination and
	daily for overall health and for abortion. Resulting foals were
	observed daily for 30 days following birth.
Results	Results shown on next page

Results	-	Study 2013-PM-1009 North Dakota Site:								
	Group		Vaccinated		firmed nant			Parturition Rate		
	1 st trimester product	/ 143	143					90%		
	1st trimeste placebo	r/ 59		54		49	9	91%		
	2 nd trimeste product	r/ 6		6		6		100%		
	3 rd trimester product	r/ 140	348 289			117		100% 94% 95%		
	Total – all animals				304		9			
	Total – product on	289				237				
	Total – placebo on	59		54		49	9	91%		
		Study 2013-PM-1009								
	Group		Vaccinated		rmed ant			Parturition Rate		
	2011 3 rd trimester	5		5		5		0%		
	2012 1 st trimester	1	1 1 53 43 26 26		1		10			
	2012 2 nd trimester	53				39 91 25 96				
	2012 3 rd trimester	26								
	Total – product	85	85		75		93	5%		
		Study 2014-PM-1009 North Dakota Site:								
			Confirmed Pregnant		Foale	Foaled Parturiti Rate		Foals Survived to End of Observation Period		
	2 nd trimester vaccinated	52	52		52	100%		51*		
	3 rd trimester vaccinated	69	69		67**	97.1%		67		
	*Lost foal af **One mare cooperator.	*Lost foal affirmed by study cooperator to be due to causes other than vaccination. **One mare died due to causes other than vaccination, as affirmed by study cooperator. All other foals were normal and healthy								
USDA Approval D										